Citi analyst David Lebowitz raised the firm’s price target on Mirum Pharmaceuticals (MIRM ... handily beating Street estimates based on stronger than expected Livmarli sales, the analyst tells ...

It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Bayer cut its full-year earnings outlook after it posted a third-quarter net loss that significantly missed consensus ...

BofA analyst Jason Gerberry raised the firm’s price target on Jazz Pharmaceuticals (JAZZ ... trading at “highly depressed multiples,” yet offering mid-single digit sales and high-single digit bottom ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product ...

Mepsevii sales also jumped ... and justifies the increased price target to $95 based on revisions to their financial model. In other recent news, Ultragenyx Pharmaceutical (NASDAQ:RARE) Inc ...

Rigel Pharmaceuticals Inc (RIGL) reports a 44% increase in net sales and achieves positive net income, driven by robust ...

The raised stock price target to $42 per American ... remains optimistic about continued sales growth and the drug's broad prescription base. Verona Pharma's recent financial performance and ...

On Friday, Recursion Pharmaceuticals Inc (RXRX) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.17 or 2.45% from the prior close of $6.93. The stock opened ...

The raised stock price target to $42 per American Depositary ... Despite the net loss for Q3, the company remains optimistic about continued sales growth and the drug's broad prescription base. Verona ...